Blood Research

Immunoglobulin data.

Ref range
(mg/dL)
All (N=23) Control (N=6) IVIG (N=17) P
Baseline values (mg/dL)
Baseline IgA, mg/dL, median (range) 70–400 128 (40–544) 117.5 (54–149) 132 (40–544) 0.18
Baseline IgA hypogammaglobulinemia 2 (9.5) 1 (16.7) 1 (6.7) 0.5
Baseline IgM, mg/dL, median (range) 40–230 41 (8–144) 44 (8–117) 41 (12–144) 0.73
Baseline IgM hypogammaglobulinemia 9 (42.9) 2 (33.3) 7 (46.7) 0.66
Baseline IgG, mg/dL, median (range) 700–1,600 716 (321–1,783) 836.5 (404–1,262) 716 (321–1,783) 0.97
Baseline IgG hypogammaglobulinemia 10 (47.6) 3 (50) 7 (46.7) 1
Nadir values (mg/dL), median (range)
IgA Nadira) 70–400 18 (<5–42) 11 (9–33) 19 (<5–42) 0.4
Time to nadir - 101 (35–688) 82 (48–109) 119 (35–688) 0.14
IgM Nadira) 40–230 9.5 (<5–47) 10 (<5–47) 9 (<5–38) 0.93
Time to nadir - 86 (35–688) 82 (48–109) 93 (35–688) 0.45
IgG, Nadir 700–1,600 338 (221–1,006) 337 (221–587) 338 (258–1,006) 0.64
Time to nadir - 103 (28–435) 85.5 (48–109) 120.5 (28–435) 0.13
IgG <500 mg/dL, N (%) - 19 (86.4) 5 (83.3) 14 (87.5) 1
Last available immunoglobulin follow-up data, median (range)
IgAa) 70–400 31 (<5–325) 20 (10–325) 36 (<5–313) 0.5
Day from blinatumomab initiation, days - 244.5 (35–912) 109 (48–382) 285 (35–912) 0.31
IgMa) 40–230 27.5 (<5–211) 12 (<5–90) 30 (<5–211) 0.53
Day from blinatumomab initiation, days - 244.5 (35–912) 109 (48–382) 279 (35–912) 0.35
IgG 700–1,600 591.5 (221–2,346) 787 (221–1,679) 547 (268–2,346) 0.91
Day from blinatumomab initiation, days - 243 (35–912) 141.5 (48–445) 276.5 (35–912) 0.49
ANC <500 cells/µL at any time point, N (%) - 19 (82.6) 6 (100) 13 (76.5) 0.54
Time to ANC <500 cells/µL, days, median (range) - 71 (2–249) 65.5 (2–109) 96 (14–249) 0.35

All values listed as N (%) unless otherwise noted.

a)A value of <5 indicates a result below the detectable level.

Abbreviations: ANC, absolute neutrophil count; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M.

Blood Res 2022;57:135~143 https://doi.org/10.5045/br.2022.2021163
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd